CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound starting October 1 and begin covering Lilly's new obesity pill Foundayo from June 1 on its standard drug plans. This move balances coverage between Eli Lilly and Novo Nordisk, following CVS's previous deal favoring Novo's Wegovy and dropping Zepbound. Both companies' GLP-1 weight loss drugs will now be co-preferred options on CVS Caremark's standard commercial formulary, potentially benefiting 25 to 30 million Americans. CVS expects this competition to drive 10-15% savings in the weight management drug category and improve patient access to treatments.
CVS Health and Salesforce have expanded their collaboration to improve call center interactions for CVS members and providers using Salesforce's AI-driven Agentforce Health platform. This platform integrates AI agents with human support to provide re...
CVS Health announced updates to its commercial drug formularies, reintroducing Zepbound (tirzepatide) and removing coverage blocks on Foundayo, expanding affordable GLP-1 weight management medication options for members. These changes aim to increase...
Aetna, part of CVS Health, has introduced the second generation of its AI-driven Claims Assist Manager (CAM) to enhance the efficiency and accuracy of insurance claims processing. This platform uses AI to reduce processing time by over 20% for comple...
This week, investors focus on key inflation data with Thursday's core PCE price index report, the Fed's preferred inflation gauge, expected at 3.3%, influencing rate decisions under new Fed Chair Kevin Warsh. A series of Federal Reserve speeches will...
